Research Article Details

Article ID: A03489
PMID: 33985827
Source: Ultrasound Med Biol
Title: Diagnostic Performance of 2-D Shear-Wave Elastography with Propagation Maps and Attenuation Imaging in Patients with Non-Alcoholic Fatty Liver Disease.
Abstract: We aimed to investigate the diagnostic performance of new 2-D shear-wave elastography (SWE) with propagation maps and attenuation imaging (ATI) for quantification of fibrosis and steatosis in non-alcoholic fatty liver disease (NAFLD). Consecutive patients with NAFLD and healthy volunteers underwent liver stiffness measurement and steatosis quantification by means of vibration-controlled transient elastography coupled with the controlled attenuation parameter as the reference and by 2-D shear-wave elastography (2-D-SWE) with propagation maps and ATI as the investigational methods. We included 232 participants (164 in the NAFLD group and 68 in the healthy control group): 51.7%/49.3% women/men; mean age, 54.2 &#177; 15.2 y; mean body mass index, 29.4 &#177; 6.5 kg/m2. Significant correlations were found between 2-D-SWE and vibration-controlled transient elastography (r&#8239;=&#8239;0.71, p < 0.0001) and between ATI and the controlled attenuation parameter (r&#8239;=&#8239;0.72, p < 0.0001). NAFLD-specific 2-D-SWE liver stiffness measurement cutoffs were as follows-F &#8805; 2: 7.9 kPa (area under the curve [AUC]&#8239;=&#8239;0.91); F &#8805; 3: 10 kPa (AUC&#8239;=&#8239;0.92); and F&#8239;=&#8239;4: 11.4 kPa (AUC&#8239;=&#8239;0.95). For steatosis, the best cutoffs by ATI were as follows-S1&#8239;=&#8239;0.73 dB/cm/MHz (AUC&#8239;=&#8239;0.86); S2&#8239;=&#8239;0.76 dB/cm/MHz (AUC&#8239;=&#8239;0.86); and S3&#8239;=&#8239;0.80 dB/cm/MHz (AUC&#8239;=&#8239;0.83). According to Baveno VI criteria, the optimal 2-D-SWE liver stiffness measurement for diagnosing liver cirrhosis is 15.5 kPa (AUC&#8239;=&#8239;0.94), and for ruling out compensated advanced chronic liver disease it is 9.2 kPa (AUC&#8239;=&#8239;0.92). To conclude, 2-D-SWE with propagation maps and ATI is reliable for quantification of liver fibrosis and steatosis in patients with NAFLD.
DOI: 10.1016/j.ultrasmedbio.2021.03.025